FLT3 and acute myeloid leukemia: In summary, the findings reviewed in this article highlight the potential for CPX-351 use in the treatment of patients with AML and mutations in FLT3. Combination approaches with CPX-351 and FLT3 inhibitors are supported by preclinical data and initial findings from clinical studies.